CONSTRUCTION OF RECOMBINANT BCG EXPRESSING THE VP1 ANTIGEN OF ENTEROVIRUS 71 FOR THE DEVELOPMENT OF A CANDIDATE VACCINE

by

NURULHASANAH BINTI OTHMAN

Thesis submitted in fulfilment of the requirements for the degree of Master of Science

October 2006
ACKNOWLEDGEMENTS

Alhamdulillah, finally with Allah permission, I was successful to completinge this study. First of all, I would to express my special gratitude to my supervisor Prof. Zainul F. Zainuddin for giving me a chance to be his student and also for his excellence guidance in order to be an eminent scientist in the future. Special thanks for my co-supervisor, Associate Prof. Dr. Mustaffa Musa for helping me in the immunogenicity studies. All the knowledges, skills and experiences that I have grabbed during the studies are very precious and useful.

I would like to thank all my colleagues in the School of Health Sciences, Institute for Research in Molecular Medicine and School of Medical Sciences for their supports. Without them, it would have been more difficult to go through this tough journey.

Last but not least, special thanks to abah, mama, abang and adik-adik for your ‘doa’, encouragement and supports.

May Allah bless you all. Amin
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>ii</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>iii</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>x</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>xi</td>
</tr>
<tr>
<td>LIST OF APPENDICES</td>
<td>xiv</td>
</tr>
<tr>
<td>LIST OF PUBLICATIONS AND SEMINAR</td>
<td>xiv</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>xv</td>
</tr>
<tr>
<td>ABSTRAK</td>
<td>xvii</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>xix</td>
</tr>
<tr>
<td>CHAPTER 1: INTRODUCTION</td>
<td></td>
</tr>
<tr>
<td>1.0 Background</td>
<td>1</td>
</tr>
<tr>
<td>1.1 History of EV71</td>
<td>1</td>
</tr>
<tr>
<td>1.2 EV71 epidemiology and evolution</td>
<td>3</td>
</tr>
<tr>
<td>1.3 The EV71 virus</td>
<td>5</td>
</tr>
<tr>
<td>1.4 Molecular genetics of virulence in EV71</td>
<td>6</td>
</tr>
<tr>
<td>1.4.1 The VP1 gene and protein</td>
<td>6</td>
</tr>
<tr>
<td>1.4.2 The 5’ UTR region</td>
<td>9</td>
</tr>
<tr>
<td>1.5 Clinical symptoms of EV71 infection</td>
<td></td>
</tr>
<tr>
<td>1.5.1 Hand foot and mouth disease (HFMD) and Herpangina</td>
<td>11</td>
</tr>
<tr>
<td>1.5.2 Neurological disease</td>
<td>11</td>
</tr>
<tr>
<td>1.5.3 Neurogenic pulmonary oedema</td>
<td>12</td>
</tr>
<tr>
<td>1.6 Transmission of EV71</td>
<td>13</td>
</tr>
<tr>
<td>1.7 Immunity of EV71</td>
<td></td>
</tr>
<tr>
<td>1.7.1 Cell-mediated immunity</td>
<td>15</td>
</tr>
<tr>
<td>1.7.2 Humoral immunity</td>
<td>16</td>
</tr>
<tr>
<td>1.8 Diagnosis of EV71 infection</td>
<td>16</td>
</tr>
<tr>
<td>1.9 Control of EV71</td>
<td></td>
</tr>
<tr>
<td>1.9.1 Antiviral agents</td>
<td>17</td>
</tr>
</tbody>
</table>
CHAPTER 2: MATERIALS AND METHODS

2.0 Materials

2.0.1 Mice

2.0.2 Bacterial strains, culture media and growth condition

2.0.3 Plasmids

2.0.4 Chemicals

2.0.5 Antibodies

2.0.6 Kits, consumables and laboratory equipments

2.0.7 Water and sterilization

2.0.8 Media

2.0.8.1 Luria-Bertani (LB) Broth

2.0.8.2 Luria-Bertani (LB) agar

2.0.8.3 7H9 medium

2.0.8.4 7H9 agar

2.0.9 Buffers

2.0.9.1 Phosphate-buffered saline (PBS)

2.0.9.2 PBS-T20 buffer

2.0.9.3 PBS-T80

2.0.9.4 50X Tris-acetate-EDTA (TAE)

2.0.9.5 Loading buffer for agarose gel electrophoresis

2.0.9.6 Resolving gel buffer

2.0.9.7 Stacking gel buffer

2.0.9.8 Running buffer

2.0.9.9 Sample buffer for SDS-PAGE

2.0.9.10 Staining buffer for Western Blot

2.0.9.11 Towbin transfer buffer

2.0.9.12 Skimmed milk

2.0.9.13 ACK lysis buffer (6X) for lysis erythrocytes

2.0.9.14 Staining buffer for flow cytometry

2.0.10 Solutions

2.0.10.1 Ampicilin antibiotic stock solution (100 mg/ml)
2.0.10.2 Kanamycin antibiotic stock solution (10 mg/ml) 45
2.0.10.3 Isoniazide antibiotic stock solution (10 mg/ml) 45
2.0.10.4 1M Hepes 46
2.0.10.5 Ethanol 70% 46
2.0.10.6 Glycerol 80% 46
2.0.10.7 Ammonium persulfate 20% 46
2.0.10.8 Stop solution (2NH2SO4) 47
2.0.10.9 Trypan blue 0.4% 47
2.0.10.10 NaOH (1N) 47
2.0.10.11 MgCl2 (10 mM) 47
2.0.10.12 CaCl2 (100mM) 48
2.0.10.13 EDTA (0.5M; pH 8.0) 48
2.0.10.14 Sodium acetate (3M) 48
2.0.10.15 Ethidium bromide (10 mg/ml) 48
2.0.10.16 Coomassie brilliant blue protein gel stain 49
2.0.10.17 5X Coomassie destaining solution 49
2.0.10.18 Chromogenic 4-chloro-1-naftol substrate 49
2.0.10.19 NaHCO3 (3%) 50
2.0.10.20 Phenylmethylsulfonyl fluoride (PMSF, 100mM) 50

2.0.11 Enzymes

2.0.12 Molecular weight marker

2.0.12.1 DNA molecular weight marker 50

2.1 Methods

2.1.1 Preparation of working oligonucleotides stocks for assembly PCR and primers 52
2.1.2 Polymerase chain reaction 52
2.1.3 Preparation of master mix 53
2.1.4 Preparation of agarose gel and electrophoresis 53
2.1.5 DNA extraction for agarose gel 54
2.1.6 Preparation of competent cells by CaCl2 method 54
2.1.7 Transformation in CaCl2 competent cells 55
2.1.8 Preparation of BCG competent cells 56
2.1.9 Transformation of BCG 57
2.1.10 Measurement of colony forming unit (cfu) for BCG 57
2.1.11 Plasmid extraction 58
2.1.12 A-tailing protocol 59
2.1.13 Cloning of the PCR product using A/T cloning 59
2.1.14 Screening of transformants and identification of positive recombinant colonies 60
2.1.15 DNA sequencing 60
2.1.16 Restriction endonuclease digestion of DNA 61
2.1.17 Determination of purify and concentration of DNA 61
2.1.18 Rapid ligation 61
2.1.19 Glycerol stocks of BCG and rBCG 62
2.1.20 Glycerol stock of E.coli 62
2.1.21 SDS-PAGE gel electrophoresis
   2.1.21.1 Preparation of resolving buffer (10%) SDS-PAGE Mini-Protean II 62
   2.1.21.2 Preparation of stacking buffer (4.5%) SDS-PAGE Mini-Protean II 63
   2.1.21.3 Electrophoresis of SDS-PAGE gel 63
   2.1.21.4 Western Blot 63
   2.1.21.5 Purification of protein by metal chelate affinity 64
2.1.22 Immunogenicity studies
   2.1.22.1 Immunization of mice 66
   2.1.22.2 Enzyme linked Immunosorbance Assay (ELISA) 66
   2.1.22.3 Spleenocyte preparation 67
   2.1.22.4 Cell culture 68
   2.1.22.5 Proliferation assay 69
   2.1.22.6 ELISA IFN-γ and IL-4 69
   2.1.22.7 Flow cytometry analysis 70

CHAPTER 3: SYNTHESIS OF THE UBGR-VP1 FUSION GENE BY ASSEMBLY PCR
3.0 Introduction 72

3.1 Methodology and results 72

3.1.1 Assembly PCR to generate VP1 fused to UbGR genes 72

3.1.1.1 Oligonucleotide design 73

3.1.1.2 Gene assembly 77

3.1.1.3 Gene amplification 83

3.1.1.4 Cloning of APCR1 and APCR2 product into PCR®2.1-TOPO® vector 86

3.1.1.5 Analysis of insert sequence pTAPCR1 and pTAPCR2 88

3.1.2 Site-directed mutagenesis 91

3.1.2.1 PCR-based site-directed mutagenesis 91

CHAPTER 4: CONSTRUCTION MYCOBACTERIUM SHUTTLE VECTORS FOR GENE EXPRESSION IN BCG 98

4.0 Introduction 98

4.1 Cloning of APCR1 and APCR2 into pNMN013 vector 99

4.1.1 Construction of recombinant plasmid without UbGR 103

4.2 Cloning of VP1 fused to UbGR gene and VP1 gene into pNMN012 vector 105

4.3 Cloning of 85AAg85A promoter fused to signal sequence into modified pNMN-ZfE1 and pNMN-ZfE2 vectors 109

4.3.1 PCR amplification of 85AAg85A promoter fused to signal peptide and cloning into PCR®2.1-TOPO® vector 109

4.3.2 Site-directed mutagenesis to change restriction site pNMN-ZfE1 and pNMN-ZfE2 vectors. 114

4.3.3 Cloning of the 85AAg85A promoter fused to signal peptide region into pNMN-ZfE3 and pNMN-ZfE4 118

CHAPTER 5: EXPRESSION OF UbGR-VP1 FUSION GENE IN BCG AND E.COLI 121

5.0 Introduction 121

5.1 Experimental design and results
5.1.1 Transformation of recombinant plasmid into BCG Pasteur 121
5.1.2 Confirmation test of the transformed plasmids in rBCG 123
5.1.3 Expression of VP1 and UbGR-VP1 fusion genes in BCG 130

5.2 Expression of UbGR-VP1 fusion gene in E.coli
5.2.1 Cloning of UbGR-VP1 fusion gene into pRSETB expression vector 133
5.2.2 Expression of UbGR-VP1 fusion gene in pRS-E1 136

CHAPTER 6: IMMUNOGENICITY STUDIES OF UBGR-VP1 FUSION PROTEIN HUMORAL RESPONSE
6.0 Introduction 138
6.1 Methodology and results
   6.1.1 Antibody response in immunized mice 138
      6.1.1.1 Total IgG production in immunized mice serum against UbGR-VP1 or VP1 protein 139
      6.1.1.2 Antibody subclasses in rBCGV1 sera 141

CHAPTER 7: IMMUNOGENICITY STUDIES OF UBGR-VP1 FUSION PROTEIN: CELL-MEDIATED IMMUNE RESPONSE
7.0 Introduction 144
7.1 Methodology and results
   7.1.1 Culture preparation 145
   7.1.2 Lymphocyte proliferation assay 146
   7.1.3 Flow cytometry test
      7.1.3.1 Surface marker staining of mice T-lymphocytes 146
      7.1.3.2 Assessment of intracellular cytokines produced by CD4+ and CD8+ T-lymphocytes 148
   7.1.4 Assessment of IFN-γ and IL-4 in culture supernatant by ELISA 149

CHAPTER 8: DISCUSSION
8.0 Introduction 154
8.1 Construction of rBCG candidate vaccine expressing fusion protein 155
UbGR-VP1

8.2 Preparation of UbGR-VP1 fusion protein to use an antigen for animal studies 159

8.3 Immunogenicity studies: Antibody immune response 160

8.4 Immunogenicity studies: Cell-mediated immune response 161

CHAPTER 9: CONCLUSION 165

REFERENCES 166
## LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>List of bacterial species and strains used in this study</td>
<td>25</td>
</tr>
<tr>
<td>2.2</td>
<td>List of chemicals and reagents used in this study</td>
<td>32</td>
</tr>
<tr>
<td>2.3</td>
<td>List of antibodies used in this study</td>
<td>35</td>
</tr>
<tr>
<td>2.4</td>
<td>List of kits and various reagents used in this study</td>
<td>36</td>
</tr>
<tr>
<td>2.5</td>
<td>List of the equipments used in this study</td>
<td>37</td>
</tr>
<tr>
<td>2.6</td>
<td>Restriction enzymes, DNA polymerases and T4 DNA ligase</td>
<td>51</td>
</tr>
<tr>
<td>3.1</td>
<td>List of oligonucleotides for APCR1 and APCR2 fragments</td>
<td>75</td>
</tr>
<tr>
<td>3.2</td>
<td>Different dilutions of oligos mixture for template preparation in the 1st Assembly PCR</td>
<td>77</td>
</tr>
<tr>
<td>3.3</td>
<td>Primer used to amplify APCR1 and APCR2 fragments</td>
<td>83</td>
</tr>
<tr>
<td>3.4</td>
<td>List of primers used for repairing base errors in pTAPCR1</td>
<td>91</td>
</tr>
<tr>
<td>3.5</td>
<td>List of primers used for repairing base errors in pTAPCR2</td>
<td>92</td>
</tr>
<tr>
<td>4.1</td>
<td>Preparation of restriction enzyme digestion reaction</td>
<td>100</td>
</tr>
<tr>
<td>4.2</td>
<td>Preparation of restriction enzyme digestion reaction</td>
<td>105</td>
</tr>
<tr>
<td>4.3</td>
<td>A set of primer used in the PCR site-directed mutagenesis</td>
<td>114</td>
</tr>
<tr>
<td>4.4</td>
<td>Preparation of restriction enzyme digestion reaction</td>
<td>118</td>
</tr>
<tr>
<td>5.1</td>
<td>CFU of rBCG that were grown in 7H11 media plate (15 μg/ml kanamycin) after electrophoration</td>
<td>122</td>
</tr>
<tr>
<td>5.2</td>
<td>Preparation of restriction enzyme digestion reaction</td>
<td>130</td>
</tr>
<tr>
<td>8.1</td>
<td>Results for all cell-mediated immune response tests</td>
<td>164</td>
</tr>
</tbody>
</table>
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>EV71 genome structure</td>
<td>8</td>
</tr>
<tr>
<td>1.2</td>
<td>Partial alignment of VP1 deduced amino acid sequence (residue 150-200) of the EV71 isolates from Western Australia belonging to genogroup C2</td>
<td>10</td>
</tr>
<tr>
<td>1.3</td>
<td>Replication and dissemination route of EV71 infection in human body</td>
<td>14</td>
</tr>
<tr>
<td>1.4</td>
<td>Flow chart for cloning, expression and animal studies</td>
<td>23</td>
</tr>
<tr>
<td>2.1a</td>
<td>Plasmid map of pCR®2.1-TOPO® vector. (Manual TOPO cloning kit)</td>
<td>27</td>
</tr>
<tr>
<td>2.1b</td>
<td>Plasmid map of pRSETB</td>
<td>28</td>
</tr>
<tr>
<td>2.1c</td>
<td>Plasmid map of pNMN012</td>
<td>29</td>
</tr>
<tr>
<td>2.1d</td>
<td>Plasmid map of pNMN013</td>
<td>30</td>
</tr>
<tr>
<td>2.1e</td>
<td>Plasmid map of pVaxUb-VP1</td>
<td>31</td>
</tr>
<tr>
<td>3.1</td>
<td>Design of the UbGR-VP1 synthetic fusion gene.</td>
<td>74</td>
</tr>
<tr>
<td>3.2</td>
<td>Schematic diagram representing the Assembly PCR process</td>
<td>78</td>
</tr>
<tr>
<td>3.3</td>
<td>PCR parameters of 1st Assembly PCR (APCR1)</td>
<td>80</td>
</tr>
<tr>
<td>3.4</td>
<td>PCR parameters of 1st Assembly PCR (APCR2)</td>
<td>80</td>
</tr>
<tr>
<td>3.5</td>
<td>Analytical agarose gel electrophoresis of the 1st Assembly PCR (APCR1)</td>
<td>81</td>
</tr>
<tr>
<td>3.6</td>
<td>Analytical agarose gel electrophoresis of the 1st Assembly PCR (APCR2)</td>
<td>82</td>
</tr>
<tr>
<td>3.7</td>
<td>PCR parameters of the 2nd Assembly PCR (APCR1)</td>
<td>84</td>
</tr>
<tr>
<td>3.8</td>
<td>PCR parameter of the 2nd Assembly PCR (APCR2)</td>
<td>84</td>
</tr>
<tr>
<td>3.9</td>
<td>Analytical agarose gel electrophoresis of the 2nd Assembly PCR (APCR1)</td>
<td>85</td>
</tr>
<tr>
<td>3.10</td>
<td>Analytical agarose gel electrophoresis of the 2nd Assembly PCR</td>
<td>85</td>
</tr>
</tbody>
</table>
3.11 Electrophoresis gel analysis (0.8%) of pTAPCR1 and pTAPCR2 digested with EcoRI

3.12 The APCR1 alignment showed the 5 mutations occurred at positions: site 68-A replace by G, site 97-missing G, site 170-missing G, site 642-missing T and site 702-missing C. (des: refer to designed sequence, for: refer to forward primer sequence, Rev: refer to reverse primer sequence.)

3.13 The APCR2 alignment showed the 49-remove G, site 222-replace A by C, site 368-remove A and site 382-missing T. (des: refer to design sequence, for: refer to forward sequence, rev: refer to reverse sequence.)

3.14 PCR parameters used for site-directed mutagenesis

3.15 Agarose gel electrophoresis analysis (0.8%) of the site-directed mutagenesis product of pTAPCR1

3.16 Agarose gel electrophoresis analysis (0.8%) of the site-directed mutagenesis product of pTAPCR2

3.17 Agarose gel electrophoresis analysis (0.8%) of pTAPCR1 clones after repairing all the five mutations

3.18 Agarose gel electrophoresis analysis (0.8%) of pTAPCR2 clones after repairing all the four mutations

4.1 Schematic diagram represented the cloning procedure of UbGR-VP1 fusion gene and VP1 gene

4.2 0.8% gel electrophoresis analysis of pNMN-E1VP1 clones

4.3 0.8% gel electrophoresis analysis of pNMN-E1VP2 clones

4.4 0.8% gel electrophoresis analysis of digested and undigested plasmid (pNMN-ZfE1)

4.5 0.8% of gel electrophoresis analysis of pNMN-ZfE2

4.6 1% agarose gel electrophoresis analysis of PCR amplified Ag85A promoter fused to signal peptide fragment

4.7 1% agarose gel electrophoresis for restriction enzyme analysis of recombinant plasmids expected to contain Ag85A promoter and signal peptide

4.8 DNA and amino acid sequences of the Ag85A promoter and signal...
Peptide sequence with some modifications. (Blue alphabets designate restriction enzyme sites, black alphabets designate the promoter site, red alphabets designate signal peptide sequence and green alphabets refer to the FLAG epitope.)

4.9 Site-directed mutagenesis PCR parameters used to change BamHI to AflII.

4.10 Schematic representation of the cloning of the Ag85A promoter and signal peptide sequence in the construction of mycobacterium shuttle plasmids for expression in BCG.

4.11 1% agarose gel electrophoresis analysis of modified plasmids.

4.12 (A) 0.8% agarose gel electrophoresis analysis of pNMN-E5VP1 clone (B) of pNMN-E6VP1 clone.

5.1 Agarose gel electrophoresis (0.8%) of PCR products from rBCG colonies.

5.2 Agarose gel electrophoresis (0.8%) of pNMN012, pNMN-E5VP1 and pNMN-E6VP1, pNMN-E1VP1, pNMN-E2VP1, pNMN-ZfE1, pNMN-ZfE2 plasmids in rBCGs.

5.3 A) SDS-PAGE B) Western blot analysis of recombinant BCG transformed with pNMN-E5VP1.

5.4 A) SDS-PAGE B) Western blot analysis of recombinant BCG transformed with pNMN-E6VP1.

5.5 0.8% agarose gel electrophoresis analysis of pRS-E1.

5.6 SDS-PAGE protein profile analysis of NHpRS-E1 and NHpRSET.

5.7 Western blot analysis of NHpRS-E1 and NHpRSET using 6-Histidine monoclonal antibody.

5.8 SDS-PAGE protein profiles analysis of purified UbGR-VP1 fusion protein from NHpRS-E1.

6.1 OD values of the total IgG in sera of immunized mice. * denotes p<0.05.

6.2 Mean OD of IgG1 in Pre-immune, BCGnhC and rBCGV1 sera against UbGR-VP1 antigen. * denotes p<0.05.

6.3 Mean OD of IgG2a in Pre-immune, BCGnhC and rBCGV1 sera against UbGR-VP1 antigen. * denotes p<0.05.

7.1 Stimulation index (SI) of lymphocytes stimulated with UbGR-VP1. * denotes p<0.05.

7.2 The percentage of CD4+ T-Cells expressing intracellular IL-2, IL-4 and IFN-γ upon stimulation with UbGR-VP1 antigen.
7.3 The percentage of CD8⁺ T-Cells expressing intracellular IL-2 and IFN-γ upon stimulation with UbGR-VP1 antigen

7.4 Concentration of IFN-γ extracellular cytokines of vaccinated mice. *denotes $p<0.05$

7.5 Concentration of IL-4 extracellular cytokines of vaccinated mice. *denotes $p<0.05$

LIST OF APPENDICES

1.1 DNA and amino acid sequences of Ag85A promoter, signal sequence and UbGR-VP1 fusion gene in the pNMN-E5VP1 recombinant plasmid

1.2 DNA and amino acid sequences of Ag85A promoter, signal sequence and VP1 gene in the pNMN-E6VP1 recombinant plasmid

1.3 DNA and amino acid sequences of VP1-UbGR-UbGR-VP1. Colour alphabets refer to restriction enzyme sites.

1.4 DNA and amino acid sequences of VP1. Colour alphabets restriction enzyme sites.

LIST OF PUBLICATIONS & SEMINARS

1.1 Construction of Recombinant BCG Expressing the VP1 antigen of Enterovirus EV71 in the Development of a Candidate Vaccine

1.2 Construction of a synthetic VP1 Gene of the enterovirus EV71 in the development of a candidate vaccine
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ag85A</td>
<td>antigen 85A from <em>M. tuberculosis</em></td>
</tr>
<tr>
<td>BCG</td>
<td><em>Mycobacterium bovis</em> BCG (Bacille Calmette Guerin)</td>
</tr>
<tr>
<td>BCGnhC</td>
<td>BCG strain that carries shuttle vector backbone plasmid as a control</td>
</tr>
<tr>
<td>bp</td>
<td>Base pair</td>
</tr>
<tr>
<td>CD4+ Th1</td>
<td>T helper lymphocytes</td>
</tr>
<tr>
<td>CD8+ Tc /CD8+ CTL</td>
<td>Cytotoxic T lymphocytes</td>
</tr>
<tr>
<td>EV71</td>
<td>Enterovirus 71</td>
</tr>
<tr>
<td>HFMD</td>
<td>Hand, foot and mouth disease</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>IL-2</td>
<td>Interleukin 2</td>
</tr>
<tr>
<td>IL-4</td>
<td>Interleukin 4</td>
</tr>
<tr>
<td>IL-5</td>
<td>Interleukin 5</td>
</tr>
<tr>
<td>IL-6</td>
<td>Interleukin 6</td>
</tr>
<tr>
<td>IL-10</td>
<td>Interleukin 10</td>
</tr>
<tr>
<td>IL-13</td>
<td>Interleukin 13</td>
</tr>
<tr>
<td>IRES</td>
<td>Internal ribosome entry site</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Kbp</td>
<td>Kilo base pair</td>
</tr>
<tr>
<td>KDa</td>
<td>Kilo Dalton</td>
</tr>
<tr>
<td>MHC</td>
<td>Major histocompatibility complex</td>
</tr>
<tr>
<td>MR</td>
<td>Radioactive imaging</td>
</tr>
<tr>
<td>NHpRSET</td>
<td><em>E. coli</em> (BL21 DE3) strain that carries pRSET plasmid alone as a control</td>
</tr>
<tr>
<td>NHpRS-E1</td>
<td><em>E. coli</em> (BL21 DE3) recombinant strain that carries pRS-E1 plasmid</td>
</tr>
<tr>
<td>rBCG</td>
<td>BCG recombinant strain</td>
</tr>
<tr>
<td>rBCGV1</td>
<td>BCG recombinant strain expresses UbGR-VP1 protein</td>
</tr>
<tr>
<td>rBCGV2</td>
<td>BCG recombinant strain expresses VP1 protein</td>
</tr>
<tr>
<td>Th</td>
<td>T-helper cell</td>
</tr>
<tr>
<td>Th1</td>
<td>T-helper 1</td>
</tr>
<tr>
<td>Th2</td>
<td>T-helper 2</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>UbGR, UbG and UbA</td>
<td>Type of ubiquitin</td>
</tr>
<tr>
<td>VP1</td>
<td>A virus capsid protein</td>
</tr>
<tr>
<td>WIN</td>
<td>Pleconaril (3 - {3,5-methyl-4-[ [ 3-methyl-(5-isoxazolyl) propyl] phenyl]-5-(trifluoromethyl)} - 1,2,4-oxadiazole)</td>
</tr>
<tr>
<td>XLA</td>
<td>X-linked agammaglobunemia</td>
</tr>
</tbody>
</table>
ABSTRAK

Enterovirus 71 (EV71), penyebab wabak penyakit tangan, kuku dan mulut (HMFD) di kalangan kanak-kanak telah dikenalpasti sebagai wabak yang diperlukan dikaun dalam pencegahan karena penyakit ini telah menjangkau bilangan kes yang tinggi sehingga sekarang. Salah satu cara yang berkesan untuk mengawal wabak ini adalah dengan kaedah pemvaksinan. Oleh itu, melalui kajian ini, calon vaksin rekombinan BCG terhadap virus EV71 telah dibangunkan. BCG rekombinan (rBCG) yang mengekspreskan gen sintetik yang mengkodkan protein VP1 daripada EV71 bercantum dengan komplek ubikuitin (UbGR) telah dihasilkan melalui teknik PCR himpunan setelah kedua-dua jujukan gen tersebut dioptimumkan mengikut kodon yang digunakan di dalam mikobakteria. Pengekspresian gen sintetik ini telah dipacu oleh promoter dan peptida berisyarat Ag85A daripada M. tuberculosis. Seterusnya, pengekspresian protein cantuman VP1-UbGR-UbGR-VP1 telah dihasilkan melalui pemblotan Western pada pellet sel rekombinan menggunakan antibodi poliklonal arnab yang spesifik terhadap VP1 protein. Imunisasi mencit BALB/c (H-2^d) dengan klon rBCGV1 menunjukkan adanya penghasilan antibodi yang signifikan di dalam serum
yang bertindakbalas dengan protein cantuman VP1-UbGRUbGR-VP1 yang ditulen. Antibodi subklas IgG2a dikenalpasti mempunyai aras yang tinggi dan signifikan berbanding IgG1. Splenosit yang diperolehi daripada mencit yang diimunisasi menunjukkan peningkatan gerakbalas proliferasi limfosit apabila dirangsang oleh antigen protein cantuman VP1-UbGRUbGR-VP1. Manakala, analisisa sitokin intrasel yang diekspres oleh sel T CD4⁺ dan CD8⁺ menunjukkan protein cantuman VP1-UbGRUbGR-VP1 merangsang sel T CD4⁺ dan CD8⁺ untuk mengekspreskan IL-2, IFN-γ dan IL-4. Antigen ini juga merangsang sel T CD8⁺ untuk mengekspreskan IL-2 dan IFN-γ. Analisisa sitokin ekstrasel menunjukkan aras IFN-γ yang tinggi dan signifikan apabila splenosit bertindakbalas dengan antigen VP1-UbGRUbGR-VP1. Secara keseluruhan, keputusan analisisa ujian imuniti ke atas mencit mencadangkan bahawa calon vaksin rBCGV1 dapat merangsang tindakbalas imuniti Th1 (T-helper 1) terhadap antigen yang dikaji. Keputusan-keputusan kajian ini menunjukkan rBCGV1 berpotensi dibangunkan sebagai vaksin dan kajian yang berterusan diperlukan bagi memastikan keberkesanannya.
CONSTRUCTION OF RECOMBINANT BCG EXPRESSING THE VP1 ANTIGEN OF ENTEROVIRUS 71 FOR THE DEVELOPMENT OF A CANDIDATE VACCINE

ABSTRACT

Enterovirus 71 (EV71), the causative agent of outbreaks of hand, foot and mouth disease (HFMD) in children is identified as a current outbreak that needs urgent control due to the high number of cases. Vaccination is one of the most effective methods to control the disease outbreaks. In this study, a recombinant BCG vaccine candidate was constructed against EV71. The recombinant BCG (rBCGV1) which expresses a synthetic gene encoding the VP1 protein of EV71 fused to ubiquitin complex (UbGR) which was constructed amplified using the technique of assembly PCR. The synthetic gene was codon technique after optimized for expression into mycobacterium codon bias. The Ag85A promoter and signal peptide sequence from M. tuberculosis drove was used to drive the expression and secretion of the synthetic gene expression was from M. tuberculosis. Hence, the expression of VP1-UbGR-VP1 fusion protein was revealed confirmed by Western blotting using rabbit polyclonal antibody specific to the VP1 protein and was found in the cell recombinant pellet cell by the used of of the
recombinant BCG-rabbit polyclonal antibody which specific to VP1 protein. Mice BALB/c (H-2d) that was immunized with rBCGV1 cloned showed the significant ability to induce moderate antibody production in serum in BALB/c (H-2d) mice when sera from immunized mice were tested against purified VP1-UbGRUbGR-VP1 purified fusion protein. IgG2a subclass antibody was shown to be induced at a has a significantly greater level than IgG1. Spleenocytes, which was obtained from rBCGV1-immunized mice showed significant higher level of lymphocyte proliferation when it was stimulated with VP1-UbGRUbGR-VP1 antigen compared to control. The analyses of intracellular cytokines analysis show that, which was expressed by CD4+ T cells and CD8+ T cells from rBCGV1 immunized mice, showed the were stimulated by VP1-UbGR antigen-UbGR-VP1 protein to stimulated CD4+ T cells to express significant levels of IL-2, IFN-γ and IL-4 when compared to the control. This antigen also stimulated CD8+ T cell to express IL-2 and IFN-γ. The extracellular cytokine analyses also showed the significantly higher levels of IFN-γ when it was stimulated with VP1-UbGR antigen compared to control. Overall, the immunogenicity studies results suggested that the rBCGV1 enhanced the stimulation of immune system towards the Th1 (T helper 1) pathway against the studied antigen. Data from this study also suggested the potential of rBCGV1 to be developed as a vaccine and further studies must be carried on-out to evaluate the efficacy of this candidate vaccine.
CHAPTER 1

INTRODUCTION

1.0 Background

Enterovirus 71 (EV71) is a human Enterovirus A belonging to the Enterovirus genus classified in the Picornaviridae family. Since the first outbreak of EV71 in 1969, epidemics have occurred periodically throughout the world (Takimoto et al., 1998 and Hagiwara et al., 1978). The most common manifestation observed in EV71 infected patients is childhood exanthema or also known as hand-foot-and-mouth-disease (HFMD) (McMinn, 2002). EV71 can also cause neurological disease during the acute infection case. The most severe clinical symptoms of EV71 infection associated with neurological disease are aseptic meningitis, brainstem and/or cerebellar encephalitis, and acute flaccid paralysis (AFP). Children less than 5 years of age are vulnerable to EV71 infection. Neurological complications of the infection occasionally cause permanent paralysis or death. In the Asia Pacific region, several large outbreaks of EV71 epidemics have been reported in young children with fatal brainstem encephalitis leading to high number of fatalities (Cardosa et al., 1999, Ho et al., 1999, Komatsu et al., 1999 and Lum et al., 1998). In Malaysia, 34 children were reported dead during the EV71 outbreak in Sarawak (Cardosa et al., 1999). To control these epidemics, the development of effective candidate vaccines against EV71 is important (McMinn, 2002).

1.1 History of EV71

In 1969, the first EV71 outbreak was reported in California where the virus from the stool of the infants with encephalitis (Schmidt et al., 1974). EV71 associated with severe neurological disease cases were later isolated in New York between 1972 and 1977 (Melnick, 1984). The first EV71 infection outside of the USA was reported in
Melbourne, Australia during an epidemic of aseptic meningitis between 1972 and 1973 (Kennett et al., 1974). In 1973, the first outbreak of HFMD was observed in Sweden (Blomberg et al., 1974) and Japan (Hagiwara et al., 1978).

In Europe, the first reported case of EV71 occurred in Bulgaria (1975) with the large and severe epidemics of encephalitis and AFP (Nagy et al. 1982 and Chumakov et al., 1979). 705 cases of EV71 were documented in the Bulgarian epidemic. Of that, 83.8% of the total cases occurred in children under 5 of years age and 93% were paralytic cases. Children with bulbar disease (AFP) were reported dead between 10 and 30 hours after onset of illness (Chumakov et al., 1979).

In the Asia Pacific region, EV71 cases were identified in Japan between 1973 and 1978 with low prevalence of acute neurological disease (Hagiwara et al., 1978). In 1985, a small outbreak of EV71 occurred in Hong Kong with several cases of AFP (Samuda et al., 1987). An outbreak was reported in Hubei Province, China during the winter of 1987 (Zheng et al., 1995). Several large epidemics and high-level endemic circulation have been identified since 1997 such as outbreaks in Japan (1999) (Komatsu, et al., 1999) and Singapore (1998) (Singh et al., 2000). In 1997, the first epidemic of EV71 in Malaysia occurred in Sarawak (Cardosa et al., 1999 and WHO, 1997) and later in Peninsular Malaysia in 2001 (Lum et al., 2002). In Malaysia, numerous cases of HFMD, herpangina and neurological complications including aseptic meningitis, AFP and cerebellar ataxia were reported in young children. In addition, the signal feature of the epidemic in Sarawak was the syndrome of rapidly fatal neurogenic pulmonary oedema associated with severe brainstem encephalitis, that caused 34 fatalities (Cardosa et al., 1999). In Peninsular Malaysia, 4 fatal cases were reported associated with this syndrome (Lum et al., 2002).
The largest EV71 outbreak was reported in Taiwan in 1998 (Liu et al., 2000, Hsiung and Wang, 2000 and Ho et al., 1999) which occurred in two waves. The first occurred between March and July involving the whole island and the second outbreak occurred from September to November which was confined to the southern region. Approximately 3.6 million cases were reported. 1.5 million HFMD cases were estimated to occur during this epidemic by the National Sentinel Surveillance Network and 2.1 million cases were asymptomatic (Ho, 2000a). Four hundred and five cases of severe neurological disease due to EV71 infection were documented and 78 cases were fatal due to neurogenic pulmonary oedema (Lum et al., 2002; McMinn et al., 2001a and Hsiung and Wang, 2000).

In 1999, a total of 6000 cases of HFMD occurred over a six months period from March until August and 29 cases progressed to severe neurological disease during the large outbreak in Perth, Australia (McMinn et al., 2001b). The EV71 epidemic continued to circulate in the Asia Pacific region during the year 2000 to 2001. This endemic occurred again with sporadic cases of HFMD and encephalomyelitis (Cardosa, 2006). Several fatal cases of encephalomyelitis were documented in Singapore and Peninsular Malaysia respectively in the year 2000 (Lum et al., 2002). In 2001, numerous cases of HFMD and severe encephalomyelitis were reported in Southeastern Australia (McMinn, 2002).

1.2 EV71 epidemiology and evolution

A molecular epidemiological study of EV71 was done by Hagiwara et al., (1984) to determine the variations between EV71 strains by analyzing the capsid’s polypeptide and RNase T1 sequences of the virus isolated from different regions such as Japan, Taiwan, Bulgaria, Hungary and USA. However, these methods were insufficient to identify specific EV71 genetic lineages or molecular markers of virulence.
The 5’ untranslated region (5’ UTR) of EV71 has been studied in China by comparing nucleotide sequence (Zheng et al., 1995). Significant genetic variations between EV71 strains from different locations or time of isolation were found using this technique.

Brown et al., (1995) contributed important information on the molecular epidemiology and evolution of EV71. The complete VP1 sequences of 113 EV71 isolates from all over the world were compared in their study. Three independent genetic lineages (genogroups) of EV71 (A, B, C) were identified and were shown to evolved over 30 years. More than 92% of nucleotides sequences were identical within same genogroup whereas 78 to 83% identities were found between genogroups. The EV71 BrCr strain was the only strain classified into genogroup A, whereas sub-lineages such as B1/B2 and C1/C2 were classified in genogroups B and C respectively.

Virus capsid protein (VP1) gene sequence of 18 strains from the 1998 Taiwanese epidemic including all strains isolated from fatal cases showed that the majority of these isolates belong to a new lineage within genogroup C2 (Shih et al., 2000). This finding was correlated with studies done by McMinn et al., 2001a.

In McMinn et al., 2001a studies, the complete VP1 gene sequence of 66 EV71 strains isolated in Malaysia, Singapore, Taiwan and Western Australia were compared. The study showed that two previously unidentified lineages within genogroup B (B3 and B4) found circulating in Southeast Asia between 1997 and 2001 were also later confirmed as similar to the new strain found in the Taiwanese epidemic (McMinn et al., 2001a).
Genogroup B3 was shown to be predominantly in South East Asia and was reported as the major cause of epidemics in Sarawak (1997), Singapore (1998) and Western Australia (1999) (McMinn et al., 2001a). Meanwhile, genogroup B4 was found in a small number of cases in Singapore (1997), Peninsular Malaysia (1997 to 1998) and Taiwan (1998), indicating that genogroup B4 was widespread in Asia Pacific region but was not predominant. In 2000, genogroup B4 became the cause of a large epidemic in Malaysia (Peninsular and Sarawak) and Singapore, apparently replacing genogroup B3 viruses (McMinn et al., 2001a).

Virus strains belonging to single lineages within genogroups B3 and C2 were identified during the Western Australia epidemics in 1999 (McMinn et al., 2001a). Nucleotide analysis, show that those of the genogroups B3 and C2 were highly similar with the genogroup C3 found in Sarawak (99%) and genogroup C2 found in Taiwan (98%) respectively.

A phylogenetic study of EV71 strains based on the VP4 gene sequence has been done in various countries (Shimizu et al., 1999). The results, suggest that EV71 strains from Bulgaria and Hungary belong to genotype A-1 whilst those from Malaysia were identified as a genotype A -2. Strains in genotype B were more prevalent in Japan and Taiwan. The study also showed that the European strains were distantly related to recent ‘VP1-based’ genogroup B3 and B4 isolates from the Asia Pacific region (Shimizu et al., 1999).

1.3 The EV71 virus

EV71 belongs to the human Enterovirus A species and is classified under the enterovirus genus within the Picornaviridae family. This virion consists of a non-enveloped capsid surrounding the core of 7.5kb single stranded RNA which has
positive polarity. The viral capsid is icosahedral in symmetry and is composed of 60 identical units (protomers), each consisting of 4 structural proteins VP1, VP2, VP3 and VP4, respectively.

The complete nucleotide sequence of the EV71 prototype strain BrCr has been determined. The single open reading frame (ORF) encodes a polyprotein of 2194 amino acids and is flanked by untranslated regions (UTRs) at the 5' and 3' ends. A variable length poly-A tract is located at the terminus of the 3' UTR. The polyprotein is subdivided into three regions, P1, P2 and P3, respectively. The P1 region encodes 4 viral structural proteins named as 1A-1D (VP1-VP4). Meanwhile the P2 and P3 regions encode non-structural proteins known as 2A-C and 3A-D, respectively. The functions of the 11 individual EV71 proteins are thought to be similar to that found in poliovirus and other non-polio enterovirus (Brown and Pallansch, 1995).

1.4 Molecular genetics of virulence in EV71

Neurological manifestations are important aspects in EV71 infections to determine the neurovirulence determinants in EV71. Many studies have been done and were mainly focused on the VP1 gene and its product as well as the 5'UTR region.

1.4.1 The VP1 gene and protein

The VP1 gene in the EV71 genome has been identified as the most informative region to study the evolutionary relationships of EV71 strains. The VP1 protein has a highly conserved tertiary structure and has been identified as the source of virulence determinants for several enteroviruses (Caggana et al., 1993). The VP1 protein is also thought to be the major viral neutralization determinant and has a high degree of antigenic and genetic diversity. A deep cleft on the virion surface has been identified at the junction of VP1 and VP2 and is thought to function as the site of virion attachment to
the cellular receptor (Blomberg *et al.*, 1974). No homologous recombinations have been shown to occur in the VP1 gene. Thus, the VP1 gene has been found to be the most useful in distinguishing within and between enteroviruses serotypes (Oberste *et al.*, 1999 and Oberste *et al.*, 1995).

McMinn *et al.*, (2001a) discovered that an EV71 strain in genogroup C2 of the Perth epidemic has a mutation at codon 170 causing a change from alanine to valine. The mutation was discovered through comparative analysis of the Perth VP1 deduced amino acid sequence with the VP1 consensus amino acid sequence of other EV71 strains (genogroups A, B, C and CA16). The genogroup C2 viruses were isolated from children with severe neurological disease. By contrast, this substitution mutation (alanine-valine) in position 170 was not found in viruses obtained from the numerous cases of uncomplicated HFMD (McMinn *et al.*, 2002 and McMinn, 2001a). The alanine residue at position 170 is a highly conserved region and exists in all EV71 and CA16 strains. The substitution of alanine to valine increases hydrophobicity at this site and may change the protein conformation (Garnier *et al.*, 1978). These data suggest that the mutation may be associated with the increased neurovirulence in the Perth epidemic (McMinn *et al.*, 2001b).

The amino acid (mutation alanine to valine) at position 170 is located in an α-helix structure within the E-F loop in VP1, at the interface between the protomer subunit and on the rim of the canyon. This region that may play a role in uncoating following receptor binding (Garnier *et al.*, 1978). In VP1 poliovirus protein, mutations at the E-F loop have been shown to alter receptor specificity by a mechanism thought to involve conformational change within the cleft (Wien *et al.*, 1997 and Filman *et al.*, 1989). The Garnier-Osguthorpe-Robson equation for secondary structure analysis was used by Garnier *et al.*, (1978) to study the alanine to valine substitution and the results
suggest that the change was likely to alter the protein conformation in the E-F loop from an α-helix to a β-sheet.

Fig 1.1: EV71 genome structure. The ORF is divided into three regions: the P1 region encodes four structural proteins VP1-VP4; the P2 and P3 regions encode seven non-structural proteins 2A-2C and 3A-3D, respectively. Adapted from Brown and Pallansch (1995).
1.4.2 The 5' UTR region

The 5' UTR of EV71 contain a group of conserved secondary structure element which is called the internal ribosome entry site (IRES). The IRES regulates enterovirus replication through the control of cap-independent translation of the polyprotein. Within the 5' UTR of EV71, IRES-like stem loop structure has been identified (Abubakar et al., 1999). A single nucleotide change within the poliovirus IRES resulted in a large alteration of the neurovirulence of the virus (Evans et al., 1985). Although, the EV71 IRES may play an important role in neurovirulence its actual role remains unclear because nucleotide variation linked to neurovirulence in the EV71 IRES has not been identified to date.
Fig. 1.2: Partial alignment of VP1 deduced amino acid sequence (residue 150-200) of the EV71 isolates from Western Australia belonging to genogroup C2. The mutation alanine to valine appeared in lineage I (residue 169). Adapted from McMinn, 2002.
1.5 Clinical symptoms of EV71 infection

1.5.1 Hand foot and mouth disease (HFMD) and Herpangina

HFMD have been associated most frequently with Coxsackievirus 16 (CA16), but also has been recognized in other enterovirus serotypes including EV71, CA5, CA9 and CA10 (Melnick, 1984). This illness is characterized by 3 to 4 days of fever and the development of vesicular exanthem on the buccal mucosa, tongue, gums and palate and a papulove-sicular exanthema on the hand, feet and buttock (McMinn et al., 2001b and Komatsu et al., 1999). The rashes of HFMD due to CA16 and EV71 may differ (McMinn et al., 2001b and Komatsu et al., 1999). The size of the CA16 infection vesicles is larger than those in EV71 infections. In EV71 infection, the rash is more frequently papular and/or petechial, often with areas of diffuse erythema on the trunks and limbs.

Herpangina is an illness characterized by an abrupt onset of fever and sore throat, associated with the development of raised papular lesions on the mucosa of the anterior pillars of fauces, soft palate and uvula (Hayward et al., 1989).

1.5.2 Neurological disease

EV71 has been shown to be highly neurotropic and associated with a diverse range of neurological diseases such as aseptic meningitis, brainstem and/or cerebellar encephalitis, AFP and several post-infectious neurological syndromes (Schmidt et al., 1974).
AFP associated with EV71 infection appears to be milder with higher rates of complete recovery compared to AFP due to poliovirus infection (McMinn et al., 2001b, Hayward et al., 1989 and Samuda et al., 1987). EV71 may induce AFP by several mechanisms in addition to virus-mediated destruction of the anterior horn motor neurons. This is reflected in the more varied clinical presentation of EV71-associated AFP than that seen during poliovirus infection (Alexander et al., 1994).

Brainstem encephalitis is the most severe neurological manifestation of EV71 infection. Radioactive MR imaging and post-mortem studies indicate that the medulla oblongata, reticular formation, pons and midbrain structures are most frequently involved (Lum et al., 2002, McMinn et al., 2001b and Huang et al., 1999). Myoclonus, tremor, ataxia, nystagmus and cranial nerve palsies have been presented in infected children (Huang et al., 1999 and Wang et al., 1999).

Acute cerebellar ataxia has been associated to EV71 in many previous epidemics (McMinn et al., 2001b, Komatsu et al., 1999, Nagy et al., 1982 and Ishimaru et al., 1980). A study of MR imaging of two cases of EV71 associated cerebellar ataxia indicated that the acute disease was linked to inflammation of the grey matter in both cerebellar hemispheres and variable atrophic changes of the cerebellar cortical atrophy may develop upon recovery, despite complete recovery of function (McMinn et al., 2001b).

1.5.3 Neurogenic pulmonary oedema

Neurogenic pulmonary oedema, also known as the grade III brainstem encephalitis has been associated with a rapid onset of cardiopulmonary failure (Huang et al., 1999). The fatality rate is 80% and all surviving children developed significant neurological sequelae during an epidemic in Taiwan(1999). Typically, children
develops tachycardia, tachypnoea and cyanosis between two and five days after the onset of fever, HFMD or herpangina (Lum et al., 2002 and Ho, 2000b).

1.6 Transmission of EV71

The mode of transmission of most enteroviruses including EV71 is by the faecal-oral-route via fecally contaminated materials. EV71 survive well in the external environment and are resistant to heat, desiccation and low temperature. The incubation period is characteristically 3 to 5 days between infections (Ho, 2000a). The initial sites of the EV71 replication are at the pharynx and terminal ilium (Fig. Figure 1.3). Virus is shed from the upper respiratory tract for 1 to 3 weeks and from the feces for up to 38 weeks. In an epidemic in Taiwan, the risk factors of transmission of EV71 infection were identified as positive serology for older sibling, children between 6 months and 3 years of age, the number of children in the family and history of HFMD or herpangina (Ho, 2000a).
Fig. 1.3: Replication and dissemination route of EV71 infection in human body.
1.7 Immunity of EV71

1.7.1 Cell-mediated immunity

Cell-mediated immunity is the main key component involved in host defense against most viruses including the enteroviruses. The main task of cell-mediated immunity is to kill virus-infected cells. Cytotoxic T lymphocytes CD8\(^+\) Tc (CTL) cell and T helper lymphocytes CD4\(^+\) Th1 cells are the main components of cell mediated antiviral defense (Germain, 1999). Activated Th1 cells produce a number of cytokines, including Interleukin 2 (IL-2), Interferon gamma (IFN-\(\gamma\)) and tumor necrosis factor (TNF) that defend against viruses either directly or indirectly. IFN-\(\gamma\) enhances the antiviral activity of macrophages. Meanwhile, IL-2 acts indirectly by assisting the recruitment of CTL precursors into effector population. Both IL-2 and IFN-\(\gamma\) activate NK (Natural Killer) cells, play an important role in host defense during the first days of many viral infections until a specific CTL response develops. Specific CTL activity arises within 3 to 4 days after infection, peak by 7 to 10 days, and then gradually decline. Within 7 to 10 days of primary infection, most viruses have been eliminated, paralleling the development of CTLs.

In general, CTLs recognize antigens as short fragments of proteins (8 to 10 amino acid length) bound to the major histocompatibility complex (MHC) class I molecules on the cell surface. Most of these peptide epitopes are derived from the cytosolic degradation of proteins that are synthesized within the host cell and are
translocated by specific transporters from the cytosol into the endoplasmic reticulum where they bind to MHC class I molecules. The peptide-MHC class I complex then is transported, through the Golgi apparatus, to the cell surface where it is presented to CD8+ T lymphocytes.

1.7.2 Humoral immunity

Humoral immunity plays a key role in neutralizing extracellular pathogens and therefore is crucial for the clearance of the cytopathic viruses to prevent the reinfection. In general, antibodies produce in viral infection including Immunoglobulin M (IgM), IgA and IgG. Initially, IgM will be produced in enterovirus infections including EV71 (Sheng et al., 2004). Patients with X-linked agammaglobunemia (XLA) who have been infected by enteroviruses, have the normal profile of cell mediated immunity but are defective in humoral immune response (Rotbart et al., 1998). This feature leads to chronic enterovirus meningoencephalitis with fatal outcome. This suggests that humoral immunity plays an important role in the body defense against enterovirus infection.

1.8 Diagnosis of EV71 infection

The standard diagnostic approach that has been used in detecting EV71 is by viral isolation from patient specimens including feces, throat swabs, rectal swabs, cerebrospinal fluid or vesicular fluid. The specimens are inoculated into Vero, RD or HeLa cell cultures and the cells are incubated for a least a week. Cultures exhibiting a cytopathic effect are identified by microneutralization assay with antiserum against EV71, or by an indirect immuno-fluorescent assay with monoclonal antibody against BrCr strain (Shimizu et al., 1999). However, this method is time consuming and relies on the availability of the antisera or commercial monoclonal antibodies.
To avoid these time-consuming methods, the IgM-capture enzyme linked-immunosorbant assay (ELISA) was developed for rapid detection of EV71 infection (Sheng et al., 2004 and Kuo et al., 2002). The sensitivity and specificity of the assay were 97.7% and 93.3% (Sheng et al., 2004). Viral isolation and neutralization tests were used as standards. With this assay, the EV71 infection can be detected within 4 hours.

Shin et al., (2000) established the Western blot method as a diagnosis tool by using the VP1 capsid protein of EV71 as an antigen. Using the assay, anti-VP1 IgM appeared in sera of patients with a symptomatic acute infection, while anti-VP1 IgG was observed in sera of patients with past infection. These findings suggest that detecting IgG and IgM immune responses against VP1 antigens are an effective means of determining the different phases of EV71 infection.

Various molecular assays were also developed to detect EV71 infection, these included reverse transcriptase PCR (RT-PCR) and DNA microchip arrays (Shin et al., 2003, Kuo et al., 2002 and Singh et al., 2000). RT-PCR was established by Kuo et al., (2002) to detect coxsackie A16 and EV71 which induces HFMD. Meanwhile, a DNA microchip assay for EV71 detection was developed by Shin et al., (2003) as an alternative diagnostic method and takes 6 hours. One hundred specimens were identified as positive for enteroviruses by viral culture including 67 EV71 specimens and these were tested using this microchip. The sensitivity and specificity of this novel method was 89.6% and 90.9% respectively.

1.9 Control of EV71

1.9.1 Antiviral agents

Much work have been done to develop the promising anti-enterovirus agents but few are, close to commercial release and their effects on EV71 are still being
investigated. The most promising agent and which are still under clinical trials are the WIN group of compound. The WIN compound, pleconaril (Rotbart et al., 1998) has been found to provide significant therapeutic benefit in aseptic meningitis, AFP and encephalitis due to many enteroviruses serotypes (Rotbart and A.D., 2001 and Starlin et al., 2001). Pleconaril (3 - (3,5-methyl-4-[ [ 3-methyl-(5-isoxazolyl) propyl] phenyl]-5 (trifluoromethyl)) - 1,2,4-oxadiazole) works by inhibiting the uncoating and the release of infectious viral RNA and this action inhibits the production of virions progeny.

The IVIG (intravenous immunoglobulin) or anti-inflammatory agent has been given to patients with X-linked agammaglobulinemia (XLA) and enterovirus meningoencephalitis. These patients fail to produce neutralizing antibody against enteroviruses infection. In the case of patients with chronic enteroviral meningoencephalitis, the strategy was successful. Enteroviral replication was suppressed and the cerebrospinal fluid (CSF) cultures were shown to be negative following treatment (Mease et al., 1981).

Even though these antiviral agents have high-level activity against EV71, but they still need to be further clinically evaluated. Thus, research efforts must be focused on the prevention of EV71 infection through the development of effective vaccines.

1.9.2 Vaccines

To prevent epidemics of EV71, the development of effective vaccine candidates are required for protection. Previously, a formalin-inactivated EV71 vaccine had been developed to control the Bulgarian epidemic in 1975, but has not been used since. Furthermore, no available data on the efficiency of this vaccine (Nagy et al., 1982 and Chumakov et al., 1979).

Cheng et al., (2001), constructed three candidate EV71 vaccines; a formalin-inactivated vaccine, a VP1 DNA subunit vaccine and a recombinant VP1 subunit
protein vaccine. In challenge studies of these vaccine candidates, mice groups vaccinated with the inactivated virus vaccine showed 80% survival with a challenge dosage of 2300 LD50 virus/mice. The subunit vaccines provided protection only at a lower challenge dosage of 230 LD50 virus/mouse, with 40% survival for DNA vaccine and 80% survival for the protein recombinant vaccine. The cytokines profiles produced by splenocytes showed high levels of interleukin 4 (IL-4) in the inactivated virus vaccine group, high levels of IFN-γ and interleukin 12 (IL-12) in the DNA vaccine group and high levels of interleukin 10 (IL-10) and IFN-γ in the protein recombinant vaccine group. Overall, the inactivated virus vaccine elicited a much greater magnitude of immune response as compared to the subunit vaccines, including total IgG subtypes and T helper cell responses. These data indicated that the inactivated EV71 virus vaccine is the best vaccine preparation capable of fulfilling the demand of effective control, and that VP1 subunit vaccines remain promising strategies for the development of EV71 vaccine. Suh et al., (2004) have optimised the micro carrier cell culture process to produce the inactivated EV71 virus vaccine.

The antigenic epitopes of EV71 involved in protection remain unknown. Thus, the identification of such epitopes is a major priority in vaccine research, as it will allow the development of transgenic mouse model for studies of EV71 pathogenesis and for the development of more effective vaccines (McMinn, 2002).

**1.10 Potential of recombinant BCG as a candidate vaccine against EV71 infection**

Bacille Calmette Guerin (BCG) has the potential to be developed as a vehicle for delivering foreign antigens by using recombinant DNA technology (Hetzel et al., 1998 and Stover et al., 1991). This technology is based on the transfer of a selected gene encoding an antigen capable of inducing productive immune response, to a non-pathogenic host, thereby making the production of an antigen safer and more efficient.
This approach has been used for the development of a few vaccines candidates such as against HIV (Human immunodeficiency virus type 1) (Aldovini and Young, 1991) and malaria (Norazmi and Dale, 1997), and tuberculosis (REF?).

BCG has been selected to deliver several viral antigens in a number of studies because of its unique advantages and suitability as a multivaccine vehicle. The advantages include the following:

1) BCG is the most widely used vaccine in the world, having been given to over 2500 million people since 1948, with low incidence of serious complications.
2) It can be administered at or any time after birth, and is unaffected by maternal antibodies.
3) BCG is given as a single dose
4) It is a potent adjuvant in experimental animals and human
5) BCG can be administered as an oral vaccine
6) It is the most heat stable of live vaccines
7) It is inexpensive to produce

A number of researchers have expressed viral epitopes in BCG and were able to induce immune response against these epitopes. Aldovini and Young (1991), found that rBCG which expressed the viral epitopes of HIV Gag, Pol and Env polyprotein under the control of heat shock protein promoter Hsp 70 can induce antibody production and T-cell responses against these epitopes in mice. The same approach also been used by Yasutomi et al., (1993) to express the antigen gig of simian immunodeficiency virus of rhesus monkey (SIV mac 251). Immunization with this rBCG elicited MHC class I-restricted, CD8+ SIV-mac251 gag-specific CTL in rhesus monkey.

1.11 Ubiquitin
Ubiquitin is a 76 amino acid peptide involved in controlling normal protein intracellular turnover in the cytoplasm of eukaryotic cells. Proteins that will be degraded are tagged by ubiquitin molecules through covalent attachment and presented to the proteosome chamber. In the proteosome, the target proteins will be degraded into small fragments of peptides by proteolytic enzymes. The conjugation of ubiquitin has been shown to enhance the cell mediated immune response in vivo against the antigen (Rodriguez et al., 1997 and Tobery and Siliciano, 1997).

In general, when the cells are infected by virus, the viral proteins will be conjugated to ubiquitin and transferred into proteosomes. After the degradation process, the small peptide fragments will be released and transported to MHC class I receptors on the surface of the cells. CD8⁺ CTLs will recognize the MHC class I molecule associated with the viral fragment complex and the activated CTLs will lyse the infected cells before the new virions are produced.

Rodriguez et al., (1997) constructed a DNA vaccine that encodes an antigen of the lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP) fused to mouse ubiquitin. Vaccination of this DNA vaccine in mice, resulted in the enhancement of cytotoxic T-lymphocyte (CTL) induction and antiviral protection. However, this vaccine does not appear to induce antibodies. Similar findings were reported by Tobery and Siliciano (1997) who constructed and evaluated recombinant vaccinia vectors encoding an HIV-1 antigen that has been tagged to ubiquitin.

Delogu et al., (2002) successfully developed three versions of DNA vaccines encoding the MPT64 tuberculosis antigen fused to different variants of ubiquitin (UbG, UbA and UbGR). These ubiquitin proteins are known to differentially affect the intracellular processing of the co-expressed protein. Vaccination of the 3 DNA candidate vaccines (designated as UbG64, UbA64 and UbGR64) in mice gave different
results of the immune response. The UbA64 DNA vaccine induced a weak humoral response as compared to UbG64, and a mixed population of IL-4 and IFN-γ secreting cells. Vaccination with the UbGR64 plasmid generated a strong Th1 cell response (high IFN-γ and low IL-4) in the absence of any detectable humoral response. Thus, the expression of the antigen (MPT64) fused to UbA or UbGR molecules, shifted the host towards a stronger Th1 immunity response which was characterised by low specific antibody level and high number of IFN-γ secreting cells. Mice immunized with the UbGR64 DNA vaccine showed resistance to subsequent challenge with *M. tuberculosis*. Therefore, ubiquitins appear to be useful in directing towards a particular type of immune response and has potential for use in vaccine development.

### 1.12 The aims of study

The main goal of this study is to explore the use of live recombinant *Mycobacterium bovis* BCG as candidate vaccines against EV71 infection. In addition, the use of UbGR (Delogu et al., 2002) as a tool to enhance immune response will also be explored.

The main aims of the study are:

1) To generate a synthetic Mycobacterium codon optimized VP1 gene of EV71 fused to ubiquitin (UbGR) by assembly PCR.

2) To clone the synthetic gene into a shuttle vector containing the Ag85A *M. tuberculosis* promoter for protein expression in BCG.

3) To test and evaluate the immunogenicity and safety of the rBCG candidate vaccines in a mouse model.

(See flow chart at Fig. Figure 1.45)
Production of the synthetic gene by assembly PCR

Clone into pCR®2.1®TOPO cloning vector

DNA sequencing

Clone into shuttle plasmids

Transformation into BCG

SDS PAGE and Western Blot to detect expression of viral protein in rBCG

Studies in mice model

Immunogenicity

Analyses of IgG level in serum by ELISA

Serum

Lymphocyte proliferation assay (LTT)

Analyses of intracellular cytokines by flow cytometry

Analyses of extracellular cytokines by ELISA

Splenocyte
CHAPTER 2

MATERIALS AND METHODS

This section describes the materials and general methods used in this work. Specific methods are described in the respective chapters.

2.1.2.0 Materials

2.1.2.0.1 Mice

Six to 8 week-old BALB/c (H-2d) female mice were obtained and housed in a pathogen-free environment at the animal house of the Universiti Sains Malaysia (USM), Health Campus, Kelantan. All animal care and experimental procedures were performed according to guidelines set by the Malaysian Association for Accreditation of Laboratory Animal Care and this work was approved by ethical committee, USM. They were given water and standard food pellet ad libitum.

2.1.2.2.0 Bacterial strains, culture media and growth conditions

Different E.coli strains were used for a variety of purposes during this study; these strains are listed in Table 2.1. Liquid and plate cultures as well as glycerol stocks